Difference between revisions of "Vinorelbine (Navelbine)"
| Line 7: | Line 7: | ||
==Disease for which it is used== | ==Disease for which it is used== | ||
| + | *[[Aggressive Non-Hodgkin lymphoma]] | ||
*[[Breast cancer]] | *[[Breast cancer]] | ||
*[[Cervical cancer]] | *[[Cervical cancer]] | ||
Revision as of 16:10, 15 July 2013
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Disease for which it is used
- Aggressive Non-Hodgkin lymphoma
- Breast cancer
- Cervical cancer
- Hodgkin lymphoma
- Mesothelioma
- Non-small cell lung cancer
- Ovarian cancer
- Sarcoma
- Small cell lung cancer
Patient drug information
- Vinorelbine (Navelbine) patient drug information (Chemocare)[3]
- Vinorelbine (Navelbine) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/23/1994: Initial FDA approval